Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the three main coronary arteries; (~* a delayed opacification in at least one of the main coronary arteries was documented. Delayed opacification was defines as corrected TIMI frame count \> 23 fps~Exclusion Criteria:~* comorbid cardiovascular condition other than mild coronary atherosclerosis and coronary slow flow~* refusal to participate~* discontinuation of treatment~* not returning for the follow up visit

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitroglycerin (Type: ACTIVE_COMPARATOR): sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
- Nicorandil (Type: ACTIVE_COMPARATOR): nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)

Based on this trial design, predict the completion outcome and termination type (if applicable).